Project Grant R61CA315017
Award Date 8/1/26
Completion Date 7/31/29
Dollars Obligated $224K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02115, USA
Similar Awards
- Federal Grant Award Summary The National Cancer Institute (NCI), under the Cancer Biology Research program (CFDA 93.396), awarded $237,023 to the President and Fellows of Harvard College (operating as Harvard Medical School) on March 13, 2026, through February 28, 2029. The award funds the development of high-throughput tools to track the fate of prematurely terminated transcripts in cancer cells, specifically addressing alternative polyadenylation (APA) events that drive oncogenesis independent...
- Federal Project Grant Award Summary Duke University's Office of Research Administration was awarded $402,135 by the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396) on May 1, 2026, for a three-year project extending through April 30, 2029. The award funds development of SCHICAR (Single-Cell Histone-level Chromatin Interaction and Accessibility with RNA), a novel tri-modal single-cell platform designed to simultaneously capture high-resolution three-dimensional...
- Federal Grant Award Summary The University of Chicago received a $388,234 Project Grant from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396) effective August 1, 2026, through July 31, 2029. This award funds the development and application of SNORNA-Enriched Kethoxal-Assisted RNA-RNA Sequencing (SNOKARR-SEQ), an advanced sequencing technology designed to identify small nucleolar RNA (snoRNA) targets at transcriptome-wide scale. The project addresses a...
- Federal Project Grant Award Summary The National Cancer Institute awarded a Project Grant of $418,176.00 to Sloan-Kettering Institute for Cancer Research under the Cancer Biology Research program (CFDA 93.396) for the period September 1, 2025, through August 31, 2028. This three-year award supports the advanced development and validation of programmable nucleic acid cytometry, a technology designed to isolate and profile rare cell populations from tumors and tissues. Building on the...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded $270,683 on May 5, 2026, under the Cancer Biology Research program (CFDA 93.396) to the New York Genome Center, Inc. (NYGC) for the development and validation of Paired-Break-Seq, a novel single-cell multiomics sequencing technique. This project, scheduled for completion on April 30, 2029, addresses a critical technical gap in cancer research by enabling simultaneous joint analysis of DNA double-strand breaks (DSBs),...
- Federal Grant Award Summary The National Cancer Institute awarded New York University School of Medicine a $595,993 Project Grant (CFDA 93.395: Cancer Treatment Research) effective July 16, 2026, through July 31, 2031, to develop integrated biologic technologies for selective inhibition of intracellular oncoproteins. The project aims to establish a robust platform technology enabling direct and selective manipulation of intracellular driver oncoproteins and their interactions. The research...
- Federal Project Grant Award Summary Virginia Commonwealth University received a $403,586 Project Grant from the National Cancer Institute (Cancer Biology Research program, CFDA 93.396) beginning August 1, 2025, and concluding July 31, 2027. The award supports research to develop codon-specific isotope labeling technology for nuclear magnetic resonance (NMR) resonance assignment. This novel methodology addresses critical obstacles in characterizing intrinsically disordered proteins (IDPs),...
- Federal Grant Award Summary The National Cancer Institute (NCI), under the Cancer Biology Research program (CFDA 93.396), awarded a $668,362 Project Grant to The Regents of the University of California, San Francisco on July 7, 2026, with a completion date of June 30, 2031. This five-year award supports fundamental cancer biology research focused on decoding ribosomal RNA (rRNA) modifications and their role in cancer development and progression. The research will investigate how cancer cells...
- Federal Project Grant Award Summary Northern Michigan University received a $462,153 Project Grant award from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396) on September 4, 2025, with a completion date of August 31, 2026. The award supports the development and application of D2HGLO, a novel genetically encoded fluorescent biosensor tool designed to detect and quantify the oncometabolite D-2-hydroxyglutarate (D-2-HG) in intact cells. This biosensor addresses...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded $400,614 through its Cancer Biology Research program (CFDA 93.396) to the University of Michigan, effective July 6, 2026, with a completion date of June 30, 2031. This Project Grant supports fundamental research investigating uridine metabolism as a therapeutic target in pancreatic ductal adenocarcinoma (PDA). The research addresses a critical gap in cancer treatment, as PDA is projected to become the second...